Abstract
Dysregulation of the Wnt inhibitor dickkopf-1 protein (Dkk1) has been reported in a variety of cancers. In addition, it has been linked to the progression of malignant bone disease by impairing osteoblast activity. This study investigated serum- and tissue levels of Dkk1 in breast cancer patients with- or without bone metastases. Serum Dkk1 levels were measured by ELISA in 89 breast cancer patients and 86 healthy women. Tissue levels of Dkk1 and β-catenin, a major downstream component of Wnt transduction pathway, were tested with immunohistochemical staining in 143 different tissues, including adjacent non-tumoral breast tissues, primary breast tumours, lymph nodes metastases, and bone metastases. Serum levels of Dkk1 were significantly increased in breast cancer patients without metastases compared with healthy controls and even more increased in patients with bone metastases. Tissue expression of Dkk1 was positive in 70% of tested primary breast cancer tissues and demonstrated significant correlation with histological type and PR status. Less frequent expression of Dkk1 was found in lymph nodes metastases and bone metastases compared with adjacent non-tumoral breast tissues and primary breast tumours. Tissue expression of β-catenin was positive in the vast majority of all tested tissue types indicating activated Wnt/β-catenin signalling. Our results suggested that Wnt/β-catenin signalling in breast tumours and their secondary lymph nodes- and bone metastases is dysregulated and this could be related to aberrant Dkk1 expression levels. Hence, Dkk1 protein might provide insights into the continued development of novel comprehensive and therapeutic strategies for breast cancer and its bone metastases.
Similar content being viewed by others
References
Clevers H, Loh KM, Nusse R (2014) Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. https://doi.org/10.1126/science.1248012
Gao C, Chen YG (2010) Dishevelled: the hub of Wnt signaling. Cell Signal 22:717–727
De A (2011) Wnt/Ca2+ signalling pathway: a brief overview. Acta Biochim Biophys Sin 43:745–756
Clevers H (2006) Wnt/β-catenin signaling in development and disease. Cell 127:469–480
Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J (2008) Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 121:737–746
He X, Semenov M, Tamai K et al (2004) LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: arrows point the way. Development 131:1663–1677
Mariz K, Ingolf JB, Daniel H, Teresa NJ, Erich-Franz S (2015) The Wnt inhibitor dickkopf-1: a link between breast cancer and bone metastases. Clin Exp Metastasis 32:857–866
Gyu-Beom J, Ji-Young K, Sung-Dae C, Ki-Soo P, Ji-Youn J, Hwa-Yong L, In-Sun H, Jeong-Seok N (2015) Blockade of Wnt/β-catenin signaling suppresses BC metastasis by inhibiting CSC-like phenotype. Sci Rep. https://doi.org/10.1038/srep12465
Merino VF, Cho S, Liang X, Park S, Jin K, Chen Q, Pan D, Zahnow CA, Rein AR, Sukumar S (2017) Inhibitors of STAT3, beta-catenin, and IGF-1R sensitize mouse PIK3CA mutant breast cancer to PI3K inhibitors. Mol Oncol 11:552–566
Shen T, Zhang K, Siegal GP, Wei S (2016) Prognostic value of E-cadherin and beta-catenin in triple-negative breast cancer. Am J Clin Pathol 146:603–610
Veeck J, Niederacher D, An H, Klopocki E et al (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25:3479–3488
Xu WH, Liu ZB, Yang C et al (2012) Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS ONE. https://doi.org/10.1371/journal.pone.0037624
Zhou SJ, Zhou SR, Yang XQ et al (2014) Serum Dickkopf-1 expression level positively correlates with a poor prognosis in breast cancer. Diagn Pathol. https://doi.org/10.1186/s13000-014-0161-4
Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Weigelt B, Peterse JL, van‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602. 2005
Manders K, van de Poll-Franse LV, Creemers GJ et al (2006) Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 6:179
Lipton A (2005) Management of bone metastases in breast cancer. Cur Treat Options Oncol 6:161–171
Johnson RW, Merkel AR, Page JM, Ruppender NS, Guelcher SA, Sterling JA (2014) Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis 31:945–959
Johnson RW, Mai PN, Susan SP et al (2010) TGF-β promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. Cancer Res 71:822–831
Gunn WG, Conley A, Deininger L et al (2006) A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24:986–991
Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24:425–436
Iyer SP, Beck JT, Stewart A et al (2014) A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167:366–375
Durkee BY, Qian Y, Pollom EL, King MT, Dudley SA, Shaffer JL, Chang DT, Gibbs IC, Goldhaber-Fiebert JD, Horst KC (2016) Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 34:902–909
Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140
Shao YC, Wei Y, Liu JF, Xu XY (2017) The role of Dickkopf family in cancers: from Bench to Bedside. Am J Cancer Res 7:1754–1768
Kagey MH, He X (2017) Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. Br J Pharmacol. https://doi.org/10.1111/bph.13894
Mazon M, Masi D, Carreau M, Modulating (2016) Dickkopf-1: a strategy to monitor or treat cancer? Cancers (Basel). https://doi.org/10.3390/cancers8070062
Liu Y, Tang W, Xie L et al (2014) Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis. Tumour Biol 35:3145–3154
González-Sancho JM, Aguilera O, García JM, Pendás-Franco N, Peña C, Cal S, García de Herreros A, Bonilla F, Muñoz A (2005) The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 24:1098–1103
Sheng SL, Huang G, Yu B, Qin WX (2009) Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem 55:1656–1664
Fouad YM, Mohamed HI, Kamal EM, Rasek MA (2016) Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma. Scand J Gastroenterol 51:1133–1137
Zhou Y, Liu F, Xu Q, Wang X (2010) Analysis of the expression profile of Dickkopf-1 gene in human glioma and the association with tumor malignancy. J Exp Clin Cancer Res 28:129–138
Liu JT, Guo WB, Sun JY (2017) Serum Dickkopf-1 acts as a new biomarker in human breast cancer. Minerva Med 108:334–340
Zhou XL, Qin XR, Zhang XD et al (2010) Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling. Acta Pharmacol Sin 31:202–210
Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD (2008) Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 269:67–77
Mikheey AM, Mikheeva SA, Maxwell JP et al (2008) Dickkopf-1 mediated tumor suppression in human breast carcinoma cells. Breast Cancer Res Treat 112:263–273
Forget MA, Turcotte S, Beauseigle D et al (2007) The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 96:646–653
Sato N, Yamabuki T, Takano A et al (2010) Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 70:5326–5336
Kato M, Patel MS, Levasseur R et al (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303–314
Glass DA 2nd, Bialek P, Ahn JD et al (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751–764
Christodoulides C, Scarda A, Granzotto M et al (2006) WNT10B mutations in human obesity. Diabetologia 49:678–684
Cheng SL, Shao JS, Cai J, Sierra OL, Towler DA (2008) Msx2 exerts bone anabolism via canonical Wnt signaling. J Biol Chem 283:20505–20522
Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163
Voorzanger-Rousselot N, Journe F, Doriath V et al (2009) Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcif Tissue Int 84:348–354
Voorzanger-Rousselot N, Goehrig D, Journe F et al (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97:964–970
Rachner TD, Göbel A, Thiele S (2014) Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Res. https://doi.org/10.1186/bcr3616
Göbel A, Kuhlmann JD, Link T, Wimberger P, Browne AJ, Rauner M, Hofbauer LC, Rachner TD (2017) Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients. Breast Cancer Res Treat 164:737–743
Hideshima T, Mitsiades C, Tonon G et al (2007) Understanding multiple myloma pathogenesis in the bone marrow to identify new therapeutics targets. Nat Rev Cancer 7:585–595
Qiang YW, Chen Y, Stephens O et al (2008) Myeloma derived Dickkopf-1 disrupts Wnt-regulated osteoprotegrin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112:196–207
Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y (2008) Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 123:1034–1042
Zhuang X, Zhang H, Li X, Li X, Cong M, Peng F, Yu J, Zhang X, Yang Q, Hu G (2017) Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol 19:1274–1285
Tulac S, Overgaard MT, Hamilton AE, Jumbe NL, Suchanek E, Giudice LC (2006) Dickkopf-1, an inhibitor of Wnt signaling, is regulated by progesterone in human endometrial stromal cells. J Clin Endocrinol Metab 91:1453–1461
Chen W, Zahng UW, Li Y, Zahng JW, Zahng T, Fu BS, Zahng Q, Jiang N (2016) Constitutive expression of Wnt/β-catenin target genes promotes proliferation and invasion of liver cancer stem cells. Mol Med Rep 13:3466–3474
Acar M, Çora T, Toy H, Acar H (2012) Analysis of promoter methylation of Dickkopf1 (DKK1) gene in breast cancer. Turk J Med Sci 42:1379–1387
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL (2006) Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66:5487–5494
Eads J, El-Khoueiry A, Manji G et al (2016) Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC). Ann Oncol 27(suppl_6):698
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study was approved by the local Ethic Committee of the Medical Association of the Saarland (Reference Number: 09/14). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Kasoha, M., Bohle, R.M., Seibold, A. et al. Dickkopf-1 (Dkk1) protein expression in breast cancer with special reference to bone metastases. Clin Exp Metastasis 35, 763–775 (2018). https://doi.org/10.1007/s10585-018-9937-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-018-9937-3